FDAnews
www.fdanews.com/articles/146822-stiefel-enters-agreement-with-welichem-biotech-to-acquire-topical-agent-for-psoriasis-atopic-dermatitis

Stiefel Enters Agreement With Welichem Biotech to Acquire Topical Agent for Psoriasis, Atopic Dermatitis

May 31, 2012
Stiefel, a GSK company, and Welichem Biotech have entered into an agreement for the acquisition by Stiefel of exclusive development and commercialization rights to the novel anti-inflammatory agent, WBI-1001, in all territories outside of China, Taiwan, Macao and Hong Kong.
MarketWatch